Journal Basic Info
- Impact Factor: 0.285**
- H-Index: 6
- ISSN: 2638-4558
- DOI: 10.25107/2638-4558
Major Scope
- Surgical
- Dentistry and Oral Medicine
- Signs and Symptoms-Clinical Findings
- Sports Medicine
- Nuclear Medicine
- Pharmacology and Therapeutics
- Orthopedics & Rheumatology
- Hematology
Abstract
Citation: Clin Case Rep Int. 2020;4(1):1152.DOI: 10.25107/2638-4558.1152
Durable Remission in a Patient with Erdheim-Chester Disease Carrying a BRAF V600E Mutation Under Dabrafenib Treatment
Ulrich Schneeberger, Christoph Woernle, Kiriaki Kollia, Katrin D Stumpe, Elisabeth J Rushing, Rene Bernays and Christoph Renner
Department of Oncology, Onkozentrum Hirslanden, Switzerland Department of Neurosurgery, Onkozentrum Hirslanden, Switzerland Departement of Radiology, Onkozentrum Hirslanden, Switzerland Department of Neuropathology, University Hospital Zurich, Switzerland
*Correspondance to: Ulrich Schneeberger
PDF Full Text Case Report | Open Access
Abstract:
We report on a patient with Erdheim-Chester Disease (ECD) carrying a BRAF V600E mutation with a complete regression of a dural tumor as well as brainstem signal alterations following therapy with dabrafenib for more than 2 years. Initial neuroimaging studies including CT and MRI showed dural masses bifrontoparietal and a right-sided tentorial mass in the cerebellopontine angle. Biopsy revealed ECD with a BRAF V600E mutation. The patient underwent initial therapy with vemurafenib. However, treatment was terminated due to adverse effects. Accordingly, dabrafenib therapy at a dose of 75 mg twice daily was started, which was well tolerated. Following more than two years of dabrafenib treatment, the patient remains in complete remission regarding the CNS lesions with stable skeletal lesions.
Keywords:
Cite the Article:
Schneeberger U, Woernle C, Kollia K, Stumpe KD, Rushing EJ, Bernays R, et al. Durable Remission in a Patient with Erdheim-Chester Disease Carrying a BRAF V600E Mutation Under Dabrafenib Treatment. Clin Case Rep Int. 2020; 4: 1152.